Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1990 May;43(5):357–364. doi: 10.1136/jcp.43.5.357

Chronic myeloproliferative disorders: prognostic importance of new working classification.

R Burkhardt 1, K Jaeger 1, G Kettner 1, G Helmer 1
PMCID: PMC502425  PMID: 2370304

Abstract

Variants of chronic myeloproliferative disorders (CMPD) were compared according to their clinical features and classified by bone marrow biopsy appearances. Subsequently, this classification was further evaluated using survival data and histological variables from iliac crest biopsy specimens of an additional 1391 patients, making a total of 2241 patients available for analysis of outcome. The patients were grouped again into three main classes: "typical"; "variant"; and "transformed". "Typical" comprised the "classic" groups. "Variant" included the less uniform myeloproliferative syndromes, distinguished also by more variable clinical features, a different prognosis, and a greater tendency to fibrotic and blastic transformation. "Transformed" defined the end stages of both "typical" and "variant" types. Ten subgroups were distinguished by different histology and prognosis. Particular prognostic importance was assigned to atypia and immaturity of haemopoiesis, predominance of individual haemopoietic cell line, number and anomalies of megakaryocytes and progressive fibrosis. It is suggested that the proposed subclassification would be helpful for studies of epidemiology and therapeutic trials by allowing more homogeneous groups to be recognised.

Full text

PDF
357

Images in this article

359Image
on p.359
360Image
on p.360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BOURONCLE B. A., DOAN C. A. Myelofibrosis. Clinical, hematologic and pathologic study of 110 patients. Am J Med Sci. 1962 Jun;243:697–715. doi: 10.1097/00000441-196206000-00001. [DOI] [PubMed] [Google Scholar]
  2. Bearman R. M., Pangalis G. A., Rappaport H. Acute ("malignant") myelosclerosis. Cancer. 1979 Jan;43(1):279–293. doi: 10.1002/1097-0142(197901)43:1<279::aid-cncr2820430141>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  3. Burkhardt R., Bartl R., Jäger K., Frisch B., Kettner G., Mahl G., Sund M. Chronic myeloproliferative disorders (CMPD). Pathol Res Pract. 1984 Nov;179(2):131–186. doi: 10.1016/S0344-0338(84)80124-7. [DOI] [PubMed] [Google Scholar]
  4. Burkhardt R., Bartl R., Jäger K., Frisch B., Kettner G., Mahl G., Sund M. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol. 1986 Mar;39(3):237–252. doi: 10.1136/jcp.39.3.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. CALABRESI P., MEYER O. O. Polycythemia vera. I. Clinical and laboratory manifestations. Ann Intern Med. 1959 May;50(5):1182–1202. doi: 10.7326/0003-4819-50-5-1182. [DOI] [PubMed] [Google Scholar]
  6. Castro-Malaspina H., Moore M. A. Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes. Nouv Rev Fr Hematol. 1982;24(4):221–226. [PubMed] [Google Scholar]
  7. Georgii A., Vykoupil K. F., Thiele J. Chronic megakaryocytic granulocytic myelosis-CMGM. A subtype of chronic myeloid leukemia. Virchows Arch A Pathol Anat Histol. 1980;389(3):253–268. doi: 10.1007/BF00430654. [DOI] [PubMed] [Google Scholar]
  8. Hirschberg T., Berchtold W., Rhyner K., Gmür J. Chronische myeloische Leukämie: multivariate Analyse der initialen Befunde bezüglich Auswirkung auf die mittlere Lebenserwartung. Schweiz Med Wochenschr. 1985 Dec 28;115(52):1881–1885. [PubMed] [Google Scholar]
  9. Karanas A., Silver R. T. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968 Sep;32(3):445–459. [PubMed] [Google Scholar]
  10. MODAN B., LILIENFELD A. M. POLYCYTHEMIA VERA AND LEUKEMIA--THE ROLE OF RADIATION TREATMENT. A STUDY OF 1222 PATIENTS. Medicine (Baltimore) 1965 Jul;44:305–344. doi: 10.1097/00005792-196507000-00003. [DOI] [PubMed] [Google Scholar]
  11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  12. Matsuo T., Tomonaga M., Kuriyama K., Yao E., Nonaka H., Jinnai I., Jubashi T., Yoshida Y., Amenomori T., Ichimaru M. Prognostic significance of the morphological dysplastic changes in chronic myelogenous leukemia. Leuk Res. 1986;10(3):331–337. doi: 10.1016/0145-2126(86)90030-5. [DOI] [PubMed] [Google Scholar]
  13. OSGOOD E. E. POLYCYTHEMIA VERA: AGE RELATIONSHIPS AND SURVIVAL. Blood. 1965 Sep;26:243–256. [PubMed] [Google Scholar]
  14. Oguma S., Takatsuki K., Uchino H., Kamada N., Oguma N., Kuramoto A. Factors influencing survival in Philadelphia chromosome positive chronic myelocytic leukemia. Cancer. 1982 Dec 15;50(12):2928–2934. doi: 10.1002/1097-0142(19821215)50:12<2928::aid-cncr2820501237>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  15. PERKINS J., ISRAUELS M. C., WILKINSON J. F. POLYCYTHAEMIA VERA: CLINICAL STUDIES ON A SERIES OF 127 PATIENTS MANAGED WITHOUT RADIATION THERAPY. Q J Med. 1964 Oct;33:499–518. [PubMed] [Google Scholar]
  16. PITCOCK J. A., REINHARD E. H., JUSTUS B. W., MENDELSOHN R. S. A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med. 1962 Jul;57:73–84. doi: 10.7326/0003-4819-57-1-73. [DOI] [PubMed] [Google Scholar]
  17. Rosenthal D. S., Moloney W. C. Myeloid metaplasia: a study of 98 cases. Postgrad Med. 1969 Mar;45(3):136–142. doi: 10.1080/00325481.1969.11697057. [DOI] [PubMed] [Google Scholar]
  18. SHIMKIN M. B., METTIER S. R., BIERMAN H. R. Myelocytic leukemia: an analysis of incidence, distribution and fatality, 1910-1948. Ann Intern Med. 1951 Jul;35(1):194–212. doi: 10.7326/0003-4819-35-1-194. [DOI] [PubMed] [Google Scholar]
  19. Silverstein M. N., Linman J. W. Causes of death in agnogenic myeloid metaplasia. Mayo Clin Proc. 1969 Jan;44(1):36–39. [PubMed] [Google Scholar]
  20. Sjögren U., Brandt L., Mitelman F. Relation between life expectancy and composition of the bone marrow at diagnosis of chronic myeloid leukaemia. Scand J Haematol. 1974;12(5):369–373. doi: 10.1111/j.1600-0609.1974.tb00223.x. [DOI] [PubMed] [Google Scholar]
  21. TIVEY H. The prognosis for survival in chronic granulocytic and lymphocytic leukemia. Am J Roentgenol Radium Ther Nucl Med. 1954 Jul;72(1):68–93. [PubMed] [Google Scholar]
  22. Tubiana M., Flamant R., Attie E., Hayat M. A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients). Blood. 1968 Oct;32(4):536–548. [PubMed] [Google Scholar]
  23. WASSERMAN L. R., GILBERT H. S. SURGICAL BLEEDING IN POLYCYTHEMIA VERA. Ann N Y Acad Sci. 1964 Jul 9;115:122–138. [PubMed] [Google Scholar]
  24. Ward H. P., Block M. H. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971 Sep;50(5):357–420. doi: 10.1097/00005792-197109000-00001. [DOI] [PubMed] [Google Scholar]
  25. Wasserman L. R. A cooperative study of polycythemia vera. Ann N Y Acad Sci. 1985;459:328–333. doi: 10.1111/j.1749-6632.1985.tb20840.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES